268 related articles for article (PubMed ID: 32101771)
1. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.
Cucci MA; Grattarola M; Dianzani C; Damia G; Ricci F; Roetto A; Trotta F; Barrera G; Pizzimenti S
Free Radic Biol Med; 2020 Apr; 150():125-135. PubMed ID: 32101771
[TBL] [Abstract][Full Text] [Related]
2. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.
Ciamporcero E; Daga M; Pizzimenti S; Roetto A; Dianzani C; Compagnone A; Palmieri A; Ullio C; Cangemi L; Pili R; Barrera G
Free Radic Biol Med; 2018 Feb; 115():447-457. PubMed ID: 29248722
[TBL] [Abstract][Full Text] [Related]
4. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells.
Grattarola M; Cucci MA; Roetto A; Dianzani C; Barrera G; Pizzimenti S
Free Radic Biol Med; 2021 Oct; 174():202-210. PubMed ID: 34364982
[TBL] [Abstract][Full Text] [Related]
5. Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation.
Sun C; Han B; Zhai Y; Zhao H; Li X; Qian J; Hao X; Liu Q; Shen J; Kai G
Free Radic Biol Med; 2022 Feb; 180():220-235. PubMed ID: 35074488
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
7. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
[TBL] [Abstract][Full Text] [Related]
8. Ailanthone inhibits non-small cell lung cancer growth and metastasis through targeting UPF1/GAS5/ULK1 signaling pathway.
Fang C; Wu W; Ni Z; Liu Y; Luo J; Zhou Y; Gong C; Hu D; Yao C; Chen X; Wang L; Zhu S
Phytomedicine; 2024 Jun; 128():155333. PubMed ID: 38518633
[TBL] [Abstract][Full Text] [Related]
9. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway.
Liao W; Wang Z; Fu Z; Ma H; Jiang M; Xu A; Zhang W
Free Radic Res; 2019 Jul; 53(7):800-814. PubMed ID: 31223046
[TBL] [Abstract][Full Text] [Related]
10. NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway.
Wu Q; Zhang H; You S; Xu Z; Liu X; Chen X; Zhang W; Ye J; Li P; Zhou X
Environ Toxicol; 2023 Jul; 38(7):1678-1689. PubMed ID: 37087754
[TBL] [Abstract][Full Text] [Related]
11. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
12. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
13. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
15. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
16. p62 promotes bladder cancer cell growth by activating KEAP1/NRF2-dependent antioxidative response.
Li T; Jiang D; Wu K
Cancer Sci; 2020 Apr; 111(4):1156-1164. PubMed ID: 31967368
[TBL] [Abstract][Full Text] [Related]
17. TAK1 Regulates the Nrf2 Antioxidant System Through Modulating p62/SQSTM1.
Hashimoto K; Simmons AN; Kajino-Sakamoto R; Tsuji Y; Ninomiya-Tsuji J
Antioxid Redox Signal; 2016 Dec; 25(17):953-964. PubMed ID: 27245349
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
19. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
20. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
